Efficacy and safety of bifidobacterium quadruple viable tablets in the treatment of Helicobacter pylori-infected peptic ulcer or gastritis patients: a systematic review and meta-analysis

Jiang, Xueliang; Xu, Chunjin; Liu, Bo; Chen, Ping; Xu, Qinchang; Zhang, Lu

doi:10.1186/s12879-023-08211-1

Table 1 Characteristics of Studies Included in the Meta-Analysis.

From: Efficacy and safety of bifidobacterium quadruple viable tablets in the treatment of Helicobacter pylori-infected peptic ulcer or gastritis patients: a systematic review and meta-analysis

The first author (year)	Group	Sample size	Age	Intervention	Medicine	Method of detection	Outcomes
Guo Li et al. (2021)	treatment	54	42.37 ± 8.62	control group + Bifidobacterium quadruple viable tablets	1.5 g/once,tid,4 week	--	1,2,3,4
Guo Li et al. (2021)	control	54	43.25 ± 9.28	amoxicillin, clarithromycin, omeprazole enteric-coated tablets, colloidal bismuth pectin	bid, 4 week	--	1,2,3,4
Li He et al. (2016)	treatment	54	42.8 ± 9.5	control group + Bifidobacterium quadruple viable tablets	bid, 14d	¹⁴ C	1
Li He et al. (2016)	control	52	42.8 ± 9.5	omeprazole, amoxicillin, Ofloxacin, colloidal bismuth subcitrate	tid, 14d	¹⁴ C	1
Fangfei Zhou et.el (2021)	treatment	48	47.50 ± 9.17	control group + Bifidobacterium quadruple viable tablets	1.5 g/once, bid, 2week	¹⁴ C	1,5
Fangfei Zhou et.el (2021)	control	48	47.00 ± 9.34	amoxicillin, clarithromycin, lansoprazole, potassium bismuth citrate	bid, 2 week	¹⁴ C	1,5
Jie Chen et al. (2020)	treatment	35	34.22 ± 6.36	control group + Bifidobacterium quadruple viable tablets	1.5 g/once, tid,4 week	¹⁴ C	2,3,4,5
Jie Chen et al. (2020)	control	35	36.27 ± 4.95	clarithromycin, Ilaprazole enteric-coated tablets, Ornidazole capsules, colloidal bismuth pectin	bid, 4week	¹⁴ C	2,3,4,5
Haitao Wang et al. (2018)	treatment	50	38.1 ± 8.3	control group + Bifidobacterium quadruple viable tablets	1.0 g/once, tid,8 week	¹⁴ C	1,2,3,4,5
Haitao Wang et al. (2018)	control	50	37.2 ± 5.1	clarithromycin, Ilaprazole enteric-coated tablets, Ornidazole capsules, colloidal bismuth pectin	8 week	¹⁴ C	1,2,3,4,5
Hua Shao et al. (2018)	treatment	50	49.39 ± 5.25	control group + Bifidobacterium quadruple viable tablets	1.5 g/once,tid, 2 month	¹⁴ C	1,5
Hua Shao et al. (2018)	control	50	49.03 ± 5.28	amoxicillin, Ilaprazole enteric-coated tablets, Ornidazole capsules, colloidal bismuth pectin	2 month	¹⁴ C	1,5
Lichun Liao et al. (2016)	treatment	50	40.8 ± 10.4	control group + Bifidobacterium quadruple viable tablets	1.5 g/once,tid, 14 d	¹⁴ C	1,5
Lichun Liao et al. (2016)	control	50	44.1 ± 12.7	amoxicillin, omeprazole enteric-coated tablets, Levofloxacin, potassium bismuth citrate	14 day	¹⁴ C	1,5
Gang Wang et al. (2020)	treatment	56	47.84 ± 11.70	control group + Bifidobacterium quadruple viable tablets	1.4 g/once,bid, 14 d	--	1,5
Gang Wang et al. (2020)	control	56	47.64 ± 11.67	amoxicillin, Esomeprazole magnesium, clarithromycin and colloidal bismuth pectin	14 d	--	1,5
Jiachen Jing et al. (2017)	treatment	80	27–70	control group + Bifidobacterium quadruple viable tablets	tid, 14 d	¹³ C	1
Jiachen Jing et al. (2017)	control	80	28–69	Esomeprazole magnesium, clarithromycin, amoxicillin, colloidal bismuth pectin	14 d	¹³ C	1
Xi Yao et al. (2020)	treatment	43	46.5 ± 5.7	control group + Bifidobacterium quadruple viable tablets	tid, 2 month	¹⁴ C	1
Xi Yao et al. (2020)	control	41	46.4 ± 5.6	Esomeprazole magnesium, clarithromycin, Ornidazole capsules, colloidal bismuth pectin	2 month	¹⁴ C	1
Xingyu Liang et al. (2021)	treatment	43	48.27 ± 5.30	control group + Bifidobacterium quadruple viable tablets	tid, 10 d	¹⁴ C	1,5
Xingyu Liang et al. (2021)	control	43	48.34 ± 5.32	amoxicillin, omeprazole enteric-coated capsule, clarithromycin and colloidal bismuth pectin	10 d	¹⁴ C	1,5
Ming Deng et al. (2019)	treatment	50	42.06 ± 5.82	control group + Bifidobacterium quadruple viable tablets	4 week	¹⁴ C	1,3,4,5
Ming Deng et al. (2019)	control	50	41.73 ± 6.07	Esomeprazole enteric-soluble capsule, amoxicillin, clarithromycin and colloidal bismuth pectin	4 week	¹⁴ C	1,3,4,5
Xiaojuan Huang et al. (2021)	treatment	57	41.65 ± 8.74	control group + Bifidobacterium quadruple viable tablets	1.5 g/once, bid,2 week	¹⁴ C	1
Xiaojuan Huang et al. (2021)	control	57	42.83 ± 9.54	Rabeprazole azole, amoxicillin, clarithromycin and colloidal bismuth pectin	2week	¹⁴ C	1
Yaohuan Li et al. (2021)	treatment	49	35.69 ± 4.22	control group + Bifidobacterium quadruple viable tablets	1.5 g/once, tid,8 week	--	1,5
Yaohuan Li et al. (2021)	control	49	35.65 ± 4.18	amoxicillin, clarithromycin, omeprazole enteric-coated capsule, colloidal bismuth pectin	8week	--	1,5
Bing Zhang et al. (2017)	treatment	100	58.6 ± 5.1	control group + Bifidobacterium quadruple viable tablets	1.5 g/once,tid,2 week	--	1,5
Bing Zhang et al. (2017)	control	100	58.4 ± 5.0	potassium bismuth citrate particles, Esomeprazole, Sanzuotong nan, amoxicillin	2 week	--	1,5
Shujie Qiao et al. (2020)	treatment	70	20 ~ 73	control group + Bifidobacterium quadruple viable tablets	1.5 g/once, bid,2 week	¹⁴ C	1,5
Shujie Qiao et al. (2020)	control	70	19 ~ 71	Rabeprazole, Stomach bismuth magnesian, amoxicillin, clarithromycin	2 week	¹⁴ C	1,5
Xiaorui He et al. (2018)	treatment	108		control group + Bifidobacterium quadruple viable tablets	bid,2 week	¹⁴ C	1
Xiaorui He et al. (2018)	control	108		amoxicillin, clarithromycin, Lansoprazole tablets, potassium bismuth citrate	2 week	¹⁴ C	1

Note: 1,Hp Eradication Rates; 2, nausea and vomiting; 3, Epigastric pain; 4, acid reflux; 5, adverse reactions; ¹⁴ C, C14 Breath test; d,day; bid, twice a day; tid, three times a day

Back to article page

ISSN: 1471-2334

Contact us

Submission enquiries: bmcinfectiousdiseases@biomedcentral.com
General enquiries: ORSupport@springernature.com

BMC Infectious Diseases

Contact us